Article Information
History
- December 30, 2021.
Article Versions
- Version 1 (December 28, 2021 - 12:56).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Eleanor G. Bentley1,
- Adam Kirby1,
- Parul Sharma1,
- Anja Kipar1,2,
- Daniele F. Mega1,
- Chloe Bramwell1,
- Rebekah Penrice-Randal1,
- Tessa Prince1,
- Jonathan C. Brown3,
- Jie Zhou3,
- Gavin R. Screaton4,
- Wendy S. Barclay3,
- Andrew Owen5,
- Julian A. Hiscox1,6,7 and
- James P. Stewart1,6,8,*
- 1Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
- 2Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, University of Zurich, Switzerland
- 3Department of Infectious Disease, Imperial College London, London, UK
- 4Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 5Department of Pharmacology and Therapeutics, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, UK
- 6Department of Preventive Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, China
- 7Infectious Diseases Horizontal Technology Centre (ID HTC), A*STAR, Singapore
- 8Department of Infectious Disease, University of Georgia, Georgia, USA
- ↵*Corresponding author: E. mail: j.p.stewart{at}liv.ac.uk;
Posted December 30, 2021.
SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
